Sophia Siu

In mRNA drug and vaccine immunogenicity, expression patterns matter

Sophia Siu, Brian D. Brown

us (code pays fourni par la source)

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression

Adam Marks, Sophia Siu, Filippo Bianchini, Chunxi Wang et autres

Proteins encoded by mRNA vaccines can be expressed by a diversity of transfected cell types but how cell-type-specific expression influences immunity is poorly understood. To investigate this, we incorporated synthetic microRNA target sites (miRT) into lipid nanoparticle (LNP)-delivered mRNA vaccines to silence …

us (code pays fourni par la source)

Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure S3. Serum Concentrations of AMG 595 and control conjugate in mice bearing U251vIII xenografts

Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure Legends and Supplementary Table. Supplementary Table. EGFRvIII receptors/cell quantification of U251vIII and D317

Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure S2. Cell Growth inhibition in A431 cells (wild-type EGFR overexpressing cells)

Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure S1. Regression of U251vIII Human GBM Subcutaneous Xenografts Following AMG 595 Treatment

Supplementary Figure S1 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure S1. Regression of U251vIII Human GBM Subcutaneous Xenografts Following AMG 595 Treatment

Supplementary Figure Legends and Supplementary Table. from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure Legends and Supplementary Table. Supplementary Table. EGFRvIII receptors/cell quantification of U251vIII and D317

Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure S2. Cell Growth inhibition in A431 cells (wild-type EGFR overexpressing cells)

Supplementary Figure S3 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Supplementary Figure S3. Serum Concentrations of AMG 595 and control conjugate in mice bearing U251vIII xenografts

Data from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Abstract Epidermal growth factor receptor variant III (EGFRvIII) is a cancer-specific deletion mutant observed in approximately 25% to 50% of glioblastoma multiforme (GBM) patients. An antibody drug conjugate, AMG 595, composed of the maytansinoid DM1 attached to a highly selective anti-EGFRvIII antibody …

Data from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang et autres

Abstract Epidermal growth factor receptor variant III (EGFRvIII) is a cancer-specific deletion mutant observed in approximately 25% to 50% of glioblastoma multiforme (GBM) patients. An antibody drug conjugate, AMG 595, composed of the maytansinoid DM1 attached to a highly selective anti-EGFRvIII antibody …